Hsing-Chen Tsai

Hsing-Chen Tsai, Ph.D., currently serves as Associate Director at Kelonia Therapeutics since October 2022, following a tenure as Senior Scientist and Senior Manager (Team Lead) at bluebird bio from 2018 to 2022, where leadership encompassed a gene therapy pipeline for ocular disease and hematopoietic stem cell programs for rare diseases. Prior experience includes roles as Scientist II at Alector, focused on antibody therapy for Alzheimer's Disease, and as a WRDM Postdoctoral Fellow at Pfizer, developing novel behavioral assays and an optogenetic platform for CNS disorders. Hsing-Chen Tsai's academic foundation includes a Ph.D. in Neurosciences from Stanford University and multiple degrees in molecular biology and epidemiology from Harvard University and Chang Gung University.